The arena of ocular therapeutics has witnessed significant advances over the years, and a key advancement within this field has been the subconjunctival administration of liposomes.
Liposome drug delivery operates on the mechanism of encapsulating the therapeutic agents into bilayered vesicles, known as liposomes. After subconjunctival administration, these liposomes function as sustained drug release systems, gradually dispensing the encapsulated drug into the surrounding tissues.
The specific mechanism of action hinges on the inherent characteristics of liposomes, particularly their structure and composition. The liposome's lipid bilayer permits the encapsulation of both hydrophilic and lipophilic drugs, enhancing their bioavailability and permeability. In the ocular tissues, liposome-encapsulated drugs are gradually released, allowing for sustained drug action.
Different approaches have been utilized for the preparation of liposomes, with each type carrying its distinct attributes. Long circulating liposomes, often PEGylated, exhibit more longevity in the biological system, providing sustained drug release. Cationic liposomes are characterized by a positive charge that enhances their interaction with the negatively charged cell membranes. Stimuli-responsive liposomes, on the other hand, react to certain triggers such as temperature changes, pH shift, enzymatic action, or light. Such features render them particularly effective for targeted drug delivery and release. Clodronate liposomes are specifically used in immunomodulation by depleting macrophages. The use of these liposomes can help understand disease processes in the eye that involve the immune system, paving the way for possible treatments.
Subconjunctival administration of liposomes has potential applications across a range of ocular conditions. This is a targeted drug delivery approach, by using this method, drugs can be delivered to the posterior segment of the eye, including the retina and optic nerve. The controlled and sustained release of drugs can be utilized for conditions such as glaucoma, age-related macular degeneration, dry eye syndrome, uveitis, and ocular infections.
This technique boasts an array of benefits, right from the effective and precise drug delivery to the simple, non-invasive administration procedure. The subconjunctival route provides direct access to the sclera and the uvea, ensuring higher drug bioavailability. A vital advantage is the prolonged release of drugs made possible by the characteristics of liposomes, thus reducing the need for frequent dosing. Furthermore, liposomes minimize systemic absorption, thereby reducing potential systemic side-effects. They also carry the potential for the delivery of a wide range of therapeutic substances, including small molecules, proteins, and even genes.
Subconjunctival administration of liposomes represents a promising advance in ocular therapeutics. The unique attributes of liposomes, coupled with the benefits of subconjunctival administration, provide a platform for enhanced therapeutic outcomes and patient convenience. As research continues in this exciting field, the potential for harnessing this technology to address unmet needs in ocular therapy becomes increasingly clear.
At Creative Biolabs, we provide the largest and diversiform portfolio of liposome products and services. Feel free to contact us for more information.
For Research Use Only. Not For Clinical UseSupports
Online Inquiry
Creative Biolabs is a world-leading liposome provider with extensive experience in liposome preparation, custom formulation development, and characterization.
© 2026 Creative Biolabs. All rights reserved.